Bio-Rad Laboratories | BIO - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 5.86B 675M 2026-03
Agilent USD 946M 44M 2025-12
Becton, Dickinson and Co. USD 2.41B 1.72B 2025-12
Bio Techne USD 191.28M 3.16M 2025-12
Bio-Rad Laboratories USD 345.2M 1.8M 2025-12
Bruker USD 449.2M 69.8M 2025-12
Charles River Laboratories USD 271.96M 39.43M 2025-12
Danaher USD 3.59B 375M 2026-03
General Electric Aerospace USD 4.24B 439M 2026-03
Illumina USD 759M 26M 2025-12
IQVIA Holdings USD 1.12B 32M 2025-12
Laboratory Of America USD 993.2M 31.9M 2025-12
Merck USD 10.85B 2.57B 2025-12
Mettler Toledo International USD 675.44M 65.98M 2025-12
Myriad Genetics USD 146.8M 3M 2025-12
OraSure Technologies USD 11.34M 435K 2025-12
Pacific Biosciences Of California USD 15.74M 601K 2025-12
Quest Diagnostics USD 906M 33M 2026-03
Repligen USD 103.83M 3.32M 2025-12
Revvity USD 421.66M 47.06M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Siemens EUR 8.1B 567M 2025-09
Standard Biotools USD 11.38M 1.9M 2025-12
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Tosoh JPY 67.57B 10.89B 2025-09
Waters USD 557.42M 97.44M 2025-12